Cargando…

Association between germ-line HLA and immune-related adverse events

BACKGROUND: In recent years, significant progress has been made in immune checkpoint inhibitors (ICIs). However, accompanied by remarkable efficacy, a growing number of immune-related adverse events (irAEs) also arose. The mechanism of irAEs remains unclear. Previous studies indicated a positive ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Ning, Yu, Yue, Zhang, Min, Tang, Yu, Wu, Dawei, Wang, Shuhang, Fang, Yuan, Zhang, Yu, Meng, Lin, Li, Yingying, Miao, Huilei, Ma, Peiwen, Huang, Huiyao, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513190/ https://www.ncbi.nlm.nih.gov/pubmed/36177028 http://dx.doi.org/10.3389/fimmu.2022.952099

Ejemplares similares

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
por: Wang, Shuhang, et al.
Publicado: (2022)

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development
por: Wang, Shuhang, et al.
Publicado: (2022)

Targeting rare tumors: new focus for clinical research in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
por: Wang, Shuhang, et al.
Publicado: (2022)

Seven-year exclusivity and beyond for drugs of rare diseases in China
por: Jiang, Yale, et al.
Publicado: (2023)

Outcome measures of phase III anticancer drug trials in China
por: Guo, Lanwei, et al.
Publicado: (2023)

Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States
por: Huang, Huiyao, et al.
Publicado: (2022)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
por: Huang, Huiyao, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy
por: Wang, Shuhang, et al.
Publicado: (2021)

Evolution of Early-Phase Anticancer Drug Investigations in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies
por: Wang, Shuhang, et al.
Publicado: (2020)

The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
por: Huang, Huiyao, et al.
Publicado: (2022)

Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention
por: Dawei, Wu, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Feng, Yao-Ning, et al.
Publicado: (2023)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers
por: Li, Peilong, et al.
Publicado: (2021)

Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms
por: Ru, Yi, et al.
Publicado: (2021)

The remodeling of Z-DNA in the mammalian germ line
por: Meng, Yingying, et al.
Publicado: (2022)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review
por: Wang, Jiao, et al.
Publicado: (2023)

Immune-related adverse events: A bibliometric analysis
por: Jiang, Shi-Tao, et al.
Publicado: (2022)

BCG and Adverse Events in the Context of Leprosy
por: Richardus, Renate, et al.
Publicado: (2018)

HLA Class II Genes HLA-DRB1, HLA-DPB1, and HLA-DQB1 Are Associated With the Antibody Response to Inactivated Japanese Encephalitis Vaccine
por: Yao, Yufeng, et al.
Publicado: (2019)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports
por: Wang, Caie, et al.
Publicado: (2023)

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

Anticardiolipin and/or anti-β2-glycoprotein-I antibodies are associated with adverse IVF outcomes
por: Wu, Li, et al.
Publicado: (2022)

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach
por: Zhou, Jiawei, et al.
Publicado: (2023)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection
por: Li, Wuling, et al.
Publicado: (2022)

Association of HLA-DPA1, HLA-DPB1, and HLA-DQB1 Alleles With the Long-Term and Booster Immune Responses of Young Adults Vaccinated Against the Hepatitis B Virus as Neonates
por: Wang, Wen-Chang, et al.
Publicado: (2021)

HLA-H: Transcriptional Activity and HLA-E Mobilization
por: Jordier, François, et al.
Publicado: (2020)

On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events
por: Späth, Peter J., et al.
Publicado: (2015)

Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer
por: Chen, Qiong-Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hvhqndn55g54vt8465bj5rf1s